Key Takeaways

CJC-1295 is a pharmacokinetically extended GHRH analog, not a finished therapeutic platform with broad clinical proof.
Its human evidence supports a claim about prolonged endocrine stimulation of GH and IGF-1, not a claim about proven body-composition, performance, recovery, or anti-aging outcomes in the general population.
The main risk is overstating what an early endocrine signal means clinically and conflating CJC-1295 with other GH-axis peptides that have different receptors, half-lives, regulatory histories, or indications.
‍

Teichman et al., 2006; Tesamorelin overview, 2025; Sermorelin overview, 2025; GHRP-6 overview, 2025].

‍

Overview

The central scientific and compliance problem with CJC-1295 is molecule confusion layered onto a thin evidence base. The best-supported human findings come from early healthy-volunteer studies showing prolonged increases in GH and IGF-1 after subcutaneous dosing, but the public market often collapses that limited biomarker evidence into broad claims about fat loss, recovery, anti-aging, muscle gain, or "GH optimization." A second recurring error is treating CJC-1295 with DAC as interchangeable with modified GRF(1-29) or "CJC-1295 without DAC," even though the DAC moiety is the main reason the pharmacokinetic profile is so different. [Teichman et al., 2006; CJC-1295 overview, 2025; Modified GRF overview, 2025; AP, 2025]

CJC-1295 is an investigational GHRH-receptor agonist peptide whose early human studies showed prolonged stimulation of the GH/IGF-1 axis after subcutaneous administration, with an estimated human half-life in the roughly 6–8 day range because of albumin binding via the DAC component. The evidence base is not a mature efficacy program built around clinical outcomes; it is primarily a small early-phase biomarker program plus secondary summaries of halted later development. [Teichman et al., 2006; CJC-1295 overview, 2025]

No FDA-approved CJC-1295 drug product was surfaced. Current reporting describes it as an unapproved peptide circulating through compounding, clinic, and "research use only" channels, and recent reporting says FDA has described clinical data as limited while flagging serious adverse events including increased heart rate and systemic vasodilatory reaction. [The Washington Post, 2025; AP, 2025; CJC-1295 overview, 2025]

What it is

CJC-1295 is a synthetic peptide analog in the GHRH/GRF agonist family. The chemical summary lists the formula as C165H269N47O46, CAS number 446262-90-4, and route of administration as subcutaneous injection. [CJC-1295 overview, 2025]

The most important distinction is that CJC-1295 is not the same molecule as modified GRF(1-29), even though clinics and peptide vendors often blur them. The no-DAC version lacks the albumin-binding extension and therefore does not share the same prolonged exposure profile. In practical terms, this means that data, dosing logic, and safety assumptions should not be transferred back and forth between the two as if they were interchangeable. [CJC-1295 overview, 2025; Modified GRF overview, 2025]

A second problem is evidence transfer from other GH-axis peptides. Sermorelin is the short native-active GHRH(1-29) fragment; tesamorelin is a distinct 44-amino-acid GHRH analog with an approved HIV-lipodystrophy indication; GHRP-6 is a ghrelin-receptor agonist with a different receptor system and different endocrine profile. Their data can inform category context, but they do not establish CJC-1295 efficacy or safety. [Sermorelin overview, 2025; Tesamorelin overview, 2025; GHRP-6 overview, 2025]

Material	What it is	Why it cannot be collapsed into "CJC-1295"
Endogenous GHRH / GRF	Native hypothalamic hormone	Native physiology is not exogenous drug evidence.
Sermorelin / GRF(1-29)	Short functional fragment of GHRH	Short-acting and historically distinct from DAC CJC-1295.
Modified GRF(1-29)	Tetrasubstituted non-DAC analog	Often sold as "CJC-1295 without DAC"; different molecule and PK.
CJC-1295 with DAC	DAC-conjugated long-acting GHRH analog	This is the target molecule in the classic early human literature. [Teichman et al., 2006]
Tesamorelin	Different synthetic GHRH analog with an FDA-approved HIV-lipodystrophy indication	Stronger clinical evidence and a real label; not interchangeable with CJC-1295.

How it's proposed to work

The most defensible mechanistic anchor is straightforward: CJC-1295 acts as a GHRH receptor agonist at the anterior pituitary, driving endogenous GH release and downstream IGF-1 production. The underlying physiologic GHRH pathway is Gs/cAMP/PKA-linked, and CJC-1295 is positioned in accessible summaries as a synthetic analog that exploits that same signaling axis while prolonging exposure pharmacokinetically through DAC-mediated albumin association. [GHRH overview, 2025; CJC-1295 overview, 2025]

That albumin-binding feature is the main reason CJC-1295 attracted development interest. Instead of merely making the peptide more receptor-potent, the DAC strategy appears designed to slow clearance and extend the endocrine effect for days rather than minutes. This is the clearest mechanistic distinction between CJC-1295 and shorter-acting GHRH analogs such as sermorelin or modified GRF(1-29) without DAC. [CJC-1295 overview, 2025; Modified GRF overview, 2025; Sermorelin overview, 2025]

One mechanistically interesting feature is that the literature associated with CJC-1295 describes preserved pulsatile GH secretion despite continuous stimulation, which matters because it suggests the peptide does not simply flatten GH physiology into a constant nonphysiologic signal in the way exogenous GH administration can. [CJC-1295 overview, 2025]

The strongest contrast is with GHRP-6, which does not act through the GHRH receptor at all. GHRP-6 is a ghrelin/GHSR agonist, and accessible summaries describe it as having no sequence relation to GHRH despite also increasing GH release. [GHRP-6 overview, 2025]

What the evidence shows about exposure

The best-circulating human PK summary is that CJC-1295 with DAC has an estimated human half-life of about 6–8 days, a striking extension versus native GHRH fragments. Accessible summaries attribute that to albumin binding through the drug-affinity complex rather than to a fundamentally different receptor mechanism. Detailed human metabolism is still not well characterized. [CJC-1295 overview, 2025; Modified GRF overview, 2025]

In humans, the early pharmacodynamic signal was prolonged. Accessible summaries report that a single injection increased plasma GH roughly 2- to 10-fold for 6 days or longer and increased plasma IGF-1 roughly 1.5- to 3-fold for 9–11 days. With multiple doses, IGF-1 elevation was reported to persist for up to 28 days. Those are meaningful endocrine effects, but they are still endocrine biomarkers rather than proof of clinical benefit in a target disease population. [Teichman et al., 2006; CJC-1295 overview, 2025]

Common forms in circulation

The scientifically anchored form is CJC-1295 with DAC, the long-acting albumin-binding analog described in the classic preclinical and human studies. Public regulatory-grade evidence for a marketed approved product was not identified. [Teichman et al., 2006; Ionescu et al., 2005]

Consumer markets commonly sell "CJC-1295," "CJC-1295 DAC," "CJC without DAC," and "mod GRF(1-29)" with overlapping language, often stacked with ipamorelin and framed around fat loss, recovery, sleep, or anti-aging. Those market routes and benefits are not validated dosing standards or efficacy data. [Washington Post, 2025; AP, 2025; GQ, 2026]

Names and aliases

CJC-1295, CJC-1295 DAC, DAC:GRF, DAC-GRF, GRF analog, growth hormone–releasing factor analog, modified GRF(1-29), "CJC without DAC," and pairings with ipamorelin, ibutamoren/MK-677, or generic "GH secretagogue stacks" all require active molecule separation review. [Memdouh et al., 2021; Washington Post, 2025]

Regulatory status

CJC-1295 is not FDA-approved. No approved indication or current approved branded product was identified in this research pass. Recent reporting further characterizes it as part of the gray-market injectable peptide ecosystem rather than an established therapeutic product. [Washington Post, 2025; AP, 2025]

Recent reporting summarizing FDA materials states that FDA has flagged CJC-1295 for safety concerns in compounding-related guidance, including limited clinical data and reported serious adverse events such as increased heart rate and systemic vasodilatory reaction. Separate 2025–2026 reporting describes CJC-1295 as being treated in practice as a U.S. Category 2 / "Do Not Compound" peptide. [Washington Post, 2025; GQ, 2026; AP, 2025]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Prospective human interventional study of DAC CJC-1295 in defined subjects with measured endocrine endpoints.	Broad efficacy claims in obesity, anti-aging, performance, injury recovery, or disease treatment.
Animal model	In vivo rodent work using DAC CJC-1295 or clearly described analogs.	Human clinical benefit or safety certainty.
Mechanistic hypothesis	Receptor activation, albumin-binding, GH/IGF-1 signaling concepts.	"Builds muscle," "burns fat," "rejuvenates," or "recovers tissue."
Anecdotal or commercial	Clinic copy, influencer claims, peptide stacks, gray-market retail.	Any scientific efficacy or dosing claim.

Purported benefits, by evidence

Purported benefit	Evidence strength	What the evidence supports	What it does not support
Increased GH secretion	Clinical trial	Small early human studies support prolonged endogenous GH stimulation after subcutaneous DAC CJC-1295.	Does not support broad therapeutic benefit claims. [Teichman et al., 2006]
Increased IGF-1	Clinical trial	Same-molecule human evidence supports prolonged IGF-1 elevation after dosing.	Does not support "anabolic therapy" or "longevity treatment." [Teichman et al., 2006]
Better body composition / fat loss	Not supported for clinical marketing	Marketed heavily for this purpose. Same-molecule published human evidence here is endocrine, not body-composition efficacy.	"Clinically proven fat loss peptide," "weight-loss treatment," "body recomposition therapy." [Washington Post, 2025; AP, 2025]
Muscle gain	Not supported for clinical marketing	Mechanistically plausible to marketers because of GH/IGF-1 signaling.	"Builds muscle," "muscle-growth therapy," "anabolic peptide." [Washington Post, 2025; GQ, 2026]
Recovery from injury	Anecdotal or commercial	Common market claim only. No robust same-molecule controlled human recovery trials were identified.	"Accelerates healing," "repair peptide," "sports recovery treatment." [Washington Post, 2025]
Anti-aging / hormone optimization	Anecdotal or commercial	Market framing only.	"Anti-aging treatment," "restores youthful hormones," "optimizes GH safely." [AP, 2025; GQ, 2026]

Key literature

Ionescu M, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. Long-acting analog design and extended endocrine signaling concept.

Jette L, Léger R, Thibaudeau K, et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. In vivo growth-axis activity in a knockout model.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne J-P, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006. Same-molecule endocrine pharmacology in humans.

Teichman SL, et al. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006. Preserved pulsatile GH secretion under prolonged stimulation.

References

Associated Press. The trend of unproven peptides is spreading through influencers and RFK Jr. allies. 2025.
The Washington Post. Some celebrities swear by peptides, but doctors warn of serious risks. 2025.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne J-P, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006.
Ionescu M, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005.
Jette L, Léger R, Thibaudeau K, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology Endocrinology and Metabolism. 2006.

‍

CJC-1295